Lv3
330 积分 2022-03-10 加入
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
10小时前
待确认
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
13小时前
已完结
Irinotecan Plus Capecitabine as a Second-line Treatment after Failure of 5-Fluorouracil and Platinum in Patients with Advanced Gastric Cancer
18小时前
已完结
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study
1天前
已完结
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
1天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
13天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
23天前
已完结
Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
1个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
1个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
1个月前
已完结
Single-cell transcriptional diversity is a hallmark of developmental potential
皖公网安备34019202002308
